Biswa Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 12-07-2024
- Paid Up Capital ₹ 0.11 M
as on 12-07-2024
- Company Age 6 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 376.56%
(FY 2020)
- Profit 871.62%
(FY 2020)
- Ebitda 830.28%
(FY 2020)
- Net Worth 929.52%
(FY 2020)
- Total Assets 670.66%
(FY 2020)
About Biswa Pharmaceuticals
The Company is engaged in the Electrnoics Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.11 M, as per Ministry of Corporate Affairs (MCA) records.
Susanth Satapathy, Ratikanta Panigrahi, and Pavan Ambati serve as directors at the Company.
- CIN/LLPIN
U52609OR2018PTC029242
- Company No.
029242
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Aug 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Company Details
- Location
Khorda, Odisha, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Biswa Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Susanth Satapathy  | Director | 02-Aug-2018 | Current |
| Ratikanta Panigrahi | Director | 02-Aug-2018 | Current |
| Pavan Ambati | Director | 02-Aug-2018 | Current |
Financial Performance of Biswa Pharmaceuticals.
Biswa Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 376.56% increase. The company also saw a substantial improvement in profitability, with a 871.62% increase in profit. The company's net worth Soared by an impressive increase of 929.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biswa Pharmaceuticals?
Unlock access to Biswa Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Konark Habitas Private LimitedActive 28 years 11 monthsRatikanta Panigrahi and Pavan Ambati are mutual person
Prudent Securities & Network Private LimitedActive 2 months 8 daysRatikanta Panigrahi and Pavan Ambati are mutual person
- Prudent Security & Trading Private LimitedActive 2 years 6 months
Ratikanta Panigrahi and Pavan Ambati are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Biswa Pharmaceuticals?
Biswa Pharmaceuticals has a workforce of 49 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biswa Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biswa Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.